Exhibit 99.1

MediCor Ltd. Reports Second Consecutive Quarter of Double-Digit Growth

    LAS VEGAS--(BUSINESS WIRE)--Feb. 14, 2005--MediCor Ltd. (OTCBB:
MDCR) announced today its financial results for the quarter ending
Dec. 31, 2004.
    Sales for the second quarter of fiscal year 2005 were $6,145,254,
an increase of $5,838,712 over the prior year quarter.
    On a pro forma basis, sales for the quarter ending Dec. 31, 2004
increased about 25% or approximately $1,232,000 over the comparable
prior year quarter. Excluding the beneficial impact of foreign
exchange rates, this growth was approximately 20%. Pro forma results
are shown because MediCor's results include the substantial benefit
from the acquisition of Eurosilicone S.A. on July 5, 2004, which was
not part of MediCor's results in the prior year quarter.
    According to MediCor's Chief Financial Officer, Thomas R. Moyes,
"Strong unit sales drove the sales growth for the quarter.
Additionally, our worldwide effort to broaden Eurosilicone's
distribution throughout Europe and Latin America is beginning to have
an impact, and is likely to accelerate over the next year. When we
acquired Eurosilicone it was the world's third largest manufacturer
and distributor of breast implants, with approximately 17% of the
breast implant market outside the United States, where it competes
predominantly with Inamed Corp. (Nasdaq: IMDC) and Mentor Corp. (NYSE:
MNT). We believe the recent high sales growth rate of Eurosilicone,
which was higher than the industry average the last two quarters, will
continue and translate into significant market share gains in calendar
year 2005 and 2006.

    About MediCor

    MediCor Ltd. (the "company" or "MediCor") is a global health care
company that acquires, develops, manufactures and markets products
primarily for the aesthetic, plastic surgery and dermatology markets.
Current products include breast and other implants and scar management
products. The company's products are sold worldwide to hospitals,
surgery centers and physicians primarily through various distributors
as well as through some direct sales personnel. MediCor's objective is
to be a leading supplier of selected international medical devices and
technologies. To achieve this strategy, MediCor intends to build upon
and expand its business lines, primarily in the aesthetic, plastic and
reconstructive surgery and dermatology markets. MediCor intends to
accomplish this growth through the expansion of existing product lines
and offerings and through the acquisition of companies and other
assets, including intellectual property rights and distribution
rights.

    About Eurosilicone

    Eurosilicone, a wholly owned subsidiary of MediCor Ltd., develops,
manufactures and markets a full range of breast implants for the
aesthetic, plastic and reconstructive surgery markets, including
silicone gel and inflatable saline-filled breast implants, with both
round and anatomical shapes, and smooth or unique micro-textured
surfaces. Eurosilicone also markets a line of external breast
prostheses under the Maxima brand sold by its Europrotex division,
available in six different shapes and a wide range of sizes.
Eurosilicone also manufactures and markets a range of other silicone
implants, including tissue expanders, testicular implants, gluteus
implants, calf implants, nasal implants, malar implants and chin
implants.

    Forward-Looking Statements

    Statements in this press release may involve forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including forward-looking statements regarding
MediCor's future credit availability and growth plans. Such statements
are based upon the current beliefs and expectations of MediCor's
management and are subject to significant risks and uncertainties,
including but not limited to external factors such as: clinical
trials, government regulation, agreements with third-party
manufacturers, product liability or other legal factors, capital
markets and the ability to obtain additional financing, economic
factors and changes in customer spending, and other factors over many
of which management has no control. These forward-looking statements
should be evaluated together with additional information about
MediCor's business, markets, conditions and other risks and
uncertainties, which could affect MediCor's future performance, which
are contained in MediCor's Annual Report on Form 10-KSB for the year
ended June 30, 2004, and its quarterly report on Form 10Q for the
quarter ended Sept. 30, 2004, and its other filings with the
Securities and Exchange Commission available at the Securities and
Exchange Commission's Internet site (http://www.sec.gov), which are
incorporated into this press release by reference. Actual results may
vary materially because of risks and uncertainties. This press release
speaks only as of its date, and MediCor disclaims any duty to update
the information herein.

    CONTACT: MediCor Ltd., Las Vegas
             Marc S. Sperberg, 702-932-4560, ext. 308